Sionna Therapeutics, Inc. (NASDAQ:SION – Get Free Report)’s share price rose 10.2% on Tuesday . The company traded as high as $16.56 and last traded at $16.42. 118,927 shares were traded during trading, a decline of 47% from the average session volume of 224,239 shares. The stock had previously closed at $14.90.
Wall Street Analysts Forecast Growth
SION has been the topic of a number of analyst reports. TD Cowen began coverage on shares of Sionna Therapeutics in a research note on Tuesday, March 4th. They set a “buy” rating on the stock. Stifel Nicolaus assumed coverage on shares of Sionna Therapeutics in a report on Tuesday, March 4th. They issued a “buy” rating and a $32.00 price target on the stock. Finally, Guggenheim initiated coverage on shares of Sionna Therapeutics in a research report on Tuesday, March 4th. They set a “buy” rating and a $45.00 price target on the stock.
Get Our Latest Report on Sionna Therapeutics
Sionna Therapeutics Stock Down 0.1 %
About Sionna Therapeutics
We are a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (“CF”) patients by developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (“CFTR”) protein to deliver clinically meaningful benefit to CF patients.
Further Reading
- Five stocks we like better than Sionna Therapeutics
- Which Wall Street Analysts are the Most Accurate?
- 3 Undervalued Stocks You Can Buy at a Discount Now
- How to Profit From Growth Investing
- AMD Stock: Can the PC Refresh Cycle Spark a Rally?
- ETF Screener: Uses and Step-by-Step Guide
- Micron Stock Spikes 7%—3 Key Catalysts Behind the Move
Receive News & Ratings for Sionna Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sionna Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
